Urate-lowering therapy for the prevention and treatment of gout flare

Jennifer A. Tilleman; Edward M. Desimone; Richard McAuliffe

Urate-lowering therapy for the prevention and treatment of gout flare

Jennifer A. Tilleman, Edward M. Desimone, Richard McAuliffe

Department of Pharmacy Sciences

Research output: Contribution to specialist publication › Article

1 Scopus citations

Abstract

Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.

Original language	English (US)
Pages	33-37
Number of pages	5
Volume	42
No	3
Specialist publication	U.S. Pharmacist
State	Published - Mar 1 2017

All Science Journal Classification (ASJC) codes

Pharmacy
Pharmacology
Pharmaceutical Science

Fingerprint Dive into the research topics of 'Urate-lowering therapy for the prevention and treatment of gout flare'. Together they form a unique fingerprint.

Cite this

@misc{ad679daaa82d40c98d8794834d2c8b10,

title = "Urate-lowering therapy for the prevention and treatment of gout flare",

abstract = "Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.",

author = "Tilleman, {Jennifer A.} and Desimone, {Edward M.} and Richard McAuliffe",

year = "2017",

month = mar,

day = "1",

language = "English (US)",

volume = "42",

pages = "33--37",

journal = "U.S. Pharmacist",

issn = "0148-4818",

publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Urate-lowering therapy for the prevention and treatment of gout flare

AU - Tilleman, Jennifer A.

AU - Desimone, Edward M.

AU - McAuliffe, Richard

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.

AB - Gout is one of the most common rheumatologic arthritic diseases in the United States. Preventing future gout attacks requires lowering serum urate levels to promote dissolution of urate crystals, which is accomplished by reducing the production of serum uric acid or promoting its excretion. Xanthene oxidase inhibitors (XOIs), including allopurinol and febuxostat, are first-line agents for the prevention of acute attacks. Probenecid, a uricosuric agent, is an appropriate adjunctive therapy or second-line agent when XOIs are contraindicated or poorly tolerated. Recently, several third-line agents (e.g., pegloticase, lesinurad) have become available for the treatment of refractory gout.

UR - http://www.scopus.com/inward/record.url?scp=85017537116&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017537116&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:85017537116

VL - 42

SP - 33

EP - 37

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -

Urate-lowering therapy for the prevention and treatment of gout flare

Abstract

All Science Journal Classification (ASJC) codes

Other files and links

Cite this